These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23990094)

  • 21. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mumps in Poland in 2011.
    Lipke M; Paradowska-Stankiewicz I
    Przegl Epidemiol; 2013; 67(2):185-8, 311-2. PubMed ID: 24040713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the current prevention strategy based on vaccination coverage and epidemiological surveillance sufficient to achieve measles and rubella elimination in Europe?
    Plans-Rubio P
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):723-6. PubMed ID: 24807016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
    American Academy of Pediatrics. Committee on Infectious Diseases
    Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016.
    Albertson JP; Clegg WJ; Reid HD; Arbise BS; Pryde J; Vaid A; Thompson-Brown R; Echols F
    MMWR Morb Mortal Wkly Rep; 2016 Jul; 65(29):731-4. PubMed ID: 27467572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mumps in Poland in 2010].
    Głuchowska M; Paradowska-Stankiewicz I
    Przegl Epidemiol; 2012; 66(2):191-5. PubMed ID: 23101203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mumps in Poland in 2005].
    Stefanoff P
    Przegl Epidemiol; 2007; 61(2):195-8. PubMed ID: 17956031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mumps in Poland in 2001].
    Sitarska-Gołebiowska J
    Przegl Epidemiol; 2003; 57(1):39-44. PubMed ID: 12926308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timeliness of MMR vaccination--influence on vaccination coverage.
    Dannetun E; Tegnell A; Hermansson G; Törner A; Giesecke J
    Vaccine; 2004 Oct; 22(31-32):4228-32. PubMed ID: 15474712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surveillance and vaccination coverage of measles and rubella in Northern Italy.
    Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A
    Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Jun; 55(22):629-30. PubMed ID: 16761359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Australian vaccine preventable disease epidemiological review series: mumps 2008-2012.
    Bag SK; Dey A; Wang H; Beard F
    Commun Dis Intell Q Rep; 2015 Mar; 39(1):E10-8. PubMed ID: 26063086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.